Search results
Showing 1 to 15 of 21 results for budesonide
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]
In development [GID-TA11662] Expected publication date: 17 December 2025
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
NG191/9 Question What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young...
In development [GID-TA11359] Expected publication date: 27 June 2025
Question What is the clinical and cost effectiveness of prednisolone, budesonide, and beclometasone in addition to aminosalicylates...
Awaiting development [GID-TA11623] Expected publication date: TBC
Awaiting development [GID-TA11614] Expected publication date: TBC
This is a summary of the most common accessibility changes we are making in guidelines, and why
Show all sections
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
cover this group.The committee made a recommendation against offering budesonide because evidence shows thatit is not beneficial in...
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.